IDEAYA Biosciences Inc
NASDAQ:IDYA

Watchlist Manager
IDEAYA Biosciences Inc Logo
IDEAYA Biosciences Inc
NASDAQ:IDYA
Watchlist
Price: 32.835 USD -2.42% Market Closed
Market Cap: $2.9B

Net Margin

-74.6%
Current
Improving
by 1 686.3%
vs 3-y average of -1 760.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-74.6%
=
Net Income
$-160.2m
/
Revenue
$214.8m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-74.6%
=
Net Income
$-160.2m
/
Revenue
$214.8m

Peer Comparison

Country Company Market Cap Net
Margin
US
IDEAYA Biosciences Inc
NASDAQ:IDYA
2.9B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
393.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
172.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 83% of companies in the United States of America
Percentile
17th
Based on 15 072 companies
17th percentile
-74.6%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

IDEAYA Biosciences Inc
Glance View

Market Cap
2.9B USD
Industry
Biotechnology

IDEAYA Biosciences Inc. is a beacon of innovation in the burgeoning field of precision oncology, focused primarily on advancing synthetic lethality - a cutting-edge approach to cancer therapy. Founded in 2015 and headquartered in South San Francisco, California, the company is deeply entrenched in the research and development of targeted therapies to combat genetically defined cancers. The core strategy revolves around discovering and developing small molecule inhibitors that precisely align with defined genetic alterations in cancer patients. By doing so, IDEAYA aims to exploit the weaknesses in specific cancer cells while sparing normal, healthy cells, thereby enhancing treatment efficacy and minimizing adverse effects. This targeted approach represents a significant shift from traditional broad-spectrum chemotherapy, offering a more personalized and efficient treatment pathway. In terms of revenue generation, IDEAYA operates primarily through collaborations and partnerships with larger pharmaceutical companies, which are attracted by its robust pipeline and innovative approach. These strategic alliances often involve milestone payments, research funding, and potential royalties on future sales. Furthermore, IDEAYA occasionally benefits from upfront payments when entering these collaborations, adding to its revenue stream. The company's business model is not solely reliant on direct sales of developed therapies but on leveraging its scientific prowess to create valuable partnership opportunities. By effectively bridging the gap between research and clinical application, IDEAYA captivates not only the interest of the pharmaceutical giants but also the investment community, eager to back a venture at the frontier of precision cancer treatment.

IDYA Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-74.6%
=
Net Income
$-160.2m
/
Revenue
$214.8m
What is IDEAYA Biosciences Inc's current Net Margin?

The current Net Margin for IDEAYA Biosciences Inc is -74.6%, which is above its 3-year median of -1 760.9%.

How has Net Margin changed over time?

Over the last 3 years, IDEAYA Biosciences Inc’s Net Margin has increased from -105.6% to -74.6%. During this period, it reached a low of -4 733% on Jun 30, 2025 and a high of -74.6% on Sep 30, 2025.

Back to Top